An Adaptive Phase I/II Study of the Safety of CD4+ T Lymphocytes and CD34+ Hematopoietic Stem/Progenitor Cells Transduced With LVsh5/C46, a Dual Anti-HIV Gene Transfer Construct, With and Without Conditioning With Busulfan in HIV-1 Infected Adults Previously Exposed to ART
Phase of Trial: Phase I/II
Latest Information Update: 04 Oct 2018
Price : $35 *
At a glance
- Drugs Cal 1 (Primary) ; Cal-1 transduced T cells (Primary) ; Busulfan
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacogenomic
- Sponsors Calimmune
- 31 Aug 2018 Biomarkers information updated
- 06 Feb 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2016 Planned End Date changed from 1 Sep 2017 to 1 Oct 2017.